eCite Digital Repository

A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome

Citation

Mhao, NS and Al-Hilli, AS and Hadi, NR and Jamil, DA and Al-Aubaidy, HA, A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome, Diabetes & metabolic syndrome, 10S pp. S95-S98. ISSN 1871-4021 (2016) [Refereed Article]

Copyright Statement

Copyright 2015 Diabetes India

DOI: doi:10.1016/j.dsx.2015.10.001

Abstract

AIM: This study was done to illustrate the clinical and biochemical effects of ethinyl estradiol-cyproterone acetate (EE-AC) and metformin in this disease.

METHODS: This was a randomized control trial study, done on twenty-six female patients already diagnosed as cases of PCOS. Participants were divided into two study groups: group one (Group 1), received metformin of 500mg twice daily and the second group (Group 2), was given ethinyl estradiol-cyproterone acetate for 21 consecutive days followed by 7 days drug-free. The course of the treatment for both groups was continued for three consecutive months.

RESULTS: Group 1 showed a statistical significant increase in serum high density lipoprotein cholesterol (HDL-C) levels (P=0.006) and a decrease in the level of triglyceride (TG) (P=0.006). In addition, Group 1 had a significant reduction in the levels of very density lipoprotein cholesterol (VLDL-C) (P=0.006). Group 2 had a significant increase in serum TG levels (P=0.01), associated with a significant decrease in serum LDL-C (P=0.04). Serum testosterone was significantly reduced in group 1 (P=0.038). This was associated with an improvement in glucose tolerance test (GTT) and BMI in the same group (group 1). Group 2, had an improvement in the menstrual cycle control; hirsutism and acne.

CONCLUSION: This study showed that metformin treatment is beneficial in improving serum lipids; glucose homeostasis and BMI, however, the ethinyl estradiol-cyproterone acetate is superior in improving the clinical manifestation of patients with PCOS, including menstrual cycle regulation, hyperandrogenic state.

Item Details

Item Type:Refereed Article
Keywords:Ethinyl estradiol-cyproterone acetate; Metabolic regulation; Metformin; Polycystic ovarian syndrome
Research Division:Medical and Health Sciences
Research Group:Medical Biochemistry and Metabolomics
Research Field:Medical Biochemistry and Metabolomics not elsewhere classified
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Endocrine Organs and Diseases (excl. Diabetes)
Author:Jamil, DA (Dr Dina Jamil)
Author:Al-Aubaidy, HA (Dr Hayder Al-Aubaidy)
ID Code:105757
Year Published:2016
Deposited By:Medicine (Discipline)
Deposited On:2016-01-14
Last Modified:2017-11-07
Downloads:0

Repository Staff Only: item control page